This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Some months after the first Covid-19 vaccines became available, the World Health Organization (WHO) set a target of vaccinating 70% of each country’s population by the end of June 2022. Read the latest issue of Pharma Technology Focus for all this and more news, insights, data and analysis from the pharmaceutical industry.
A study led by University at Buffalo researchers has confirmed that contrary to claims by anti-vaccine proponents, COVID-19 vaccines pose only trivial risk of venous thromboembolism (VTE), or blood clots. In addition, the study found that becoming infected with COVID-19 poses a significant risk of blood clots.
Is a century-old vaccine a ‘game-changer’ for COVID-19? Anita de Waard from Elsevier and Radoslav Kirkov from Estafet tells us how a hackathon is harnessing data science to look beyond the hype and seek definitive clinical evidence. Today, the notion of ‘data science’ has permeated almost every area of society.
Countries like Estonia and Finland have taken on a completely digitised approach to their health services , integrating EHR data to efficiently prescribe medications and improve treatment strategies. Darwin EU is part of the EMA BigData Steering group that aims to increase the utility of BigData in regulatory decision-making.
Bigdata analysis can be enormously powerful in providing insights for business strategy throughout the pharma value chain, including in the acceleration of drug discovery and development, optimization of manufacturing processes, management of supply chains and the creation of innovative sales and marketing strategies.
The report also suggested that BigData was thought to be the most important partner to AI, in terms of introducing technology-related changes in the pharmaceutical sector (Figure 2). AI has been voted as the most disruptive emerging technology every year since 2020, according to the survey tracker.
Embracing Digital Transformation The role of BigData and Artificial Intelligence in healthcare is growing exponentially. Many organizations demonstrated remarkable adaptability, quickly pivoting to produce vaccines and therapeutics at unprecedented speeds. What role does digitalization play in enhancing CDMO flexibility?
According to a recent GlobalData report, healthcare professionals have – for the second year in a row – ranked artificial intelligence (AI) and BigData as the top two technologies revolutionising the pharmaceutical sector. Digital transformation is permeating the entire pharmaceutical supply chain. what it means for you.
She went on to describe another study, EAVE II , which has drawn on BREATHE’s expertise, linking patient data across the entire Scottish population to provide the first real-world evidence of the success of the COVID-19 vaccination programme in cutting risk of hospital admission.
In June 2007, AstraZeneca completed the acquisition of vaccine maker MedImmune, buying its drug-development pipeline for $15.2 This resulted in AstraZeneca becoming possibly the most talked-about pharma company in the world when its own vaccine emerged as the frontrunning candidate.
Syntegra has also engaged with the Federal Drug Administration (FDA) to evaluate the role of synthetic data in regulatory decisions, for COVID-19 and beyond.
With the COVID-19 pandemic, there has never been a time when rapid, low burden access to patient-level data, at scale, was more urgent” says Michael D.
Meanwhile, decentralisation and the BigData revolution are transforming the way researchers run clinical trials, and previously untapped geographies are emerging as new hubs for future research. Translating BigData into results BigData is another cornerstone of the digital revolution.
Led by researchers from the University of Oxford ‘s BigData Institute, the study underscores the significance of analysing viruses continually over time. The VB variant. HIV first emerged in 1920 in the Democratic Republic of Congo, and, like other viruses, researchers monitored its evolution and anticipated it would mutate.
With each passing year, pharmaceutical companies around the globe strive to deliver cutting-edge medicines, therapies and vaccines that impact the lives of millions. Pfizer’s Top 5 Best-Selling Drugs of 2022: 1) Comirnaty Comirnaty is an mRNA-based vaccine indicated for the prevention of COVID-19. billion in 2022. for a pediatric dose.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content